white → orange2 → red2
Proscaline
4-Propyloxy-3,5-dimethoxyphenethylamine
P, 4-Propoxy-3,5-DMPEA
Proscaline is a lesser-known psychedelic of the substituted phenethylamine class, structurally related to mescaline as its 4-propyloxy analog.1 Its synthesis was first published by David E. Nichols in 1977, and it was later evaluated by Alexander Shulgin, who estimated its potency at roughly five times that of mescaline.2 Shulgin documented his findings in the 1991 book PiHKAL.1 It belongs to a series of mescaline analogs including escaline and allylescaline,3 and appeared on the research chemical market in the 2010s.
Dosage & Duration
Dosage
Threshold~10 mg
Light10-30 mg
Moderate30-40 mg
Strong40-60 mg
Heavy60+ mg
Duration
Onset30-60 minutes
After Effects3-5 hours
Total8-12 hours
Subjective Effects
Proscaline produces a gentle, mescaline-like psychedelic state that develops fully within the first couple of hours and can sustain a warm, contented euphoria for the remainder of the day. The experience is frequently described as pleasant but low-key, with a peaceful, sociable character rather than a deep or revelatory one; at common doses some users find it notably uneventful. Toward the upper end of the dosage range the balance shifts toward physical load and irritability, and sleep may remain impossible for twelve hours or more, though no hangover is reported the following day.
Physical
The body load includes mild mental and physical stimulation with restlessness and occasional tremor during the come-up, alongside muscle tension, pupil dilation, appetite suppression, and sweating or chills. Pronounced wakefulness is typical, and insomnia can persist well past the peak; some users instead report drowsiness as lower-dose experiences wind down.
Cognitive
The headspace is characterized by deep peace, contentment, and a steadily building euphoria, with strong sociability and a light, joking conversational tone. Mental clarity is largely preserved even when the body feels intoxicated, but the state tends to lack enhanced clarity, deep realizations, or motivation for serious analysis, and confusion or irritability can appear, particularly at higher doses.
Emotional
Visual
Visuals are present with eyes open and closed but remain relatively subtle at common doses, with color brightening as the most consistent feature.
Tactile
Pharmacology
Pharmacodynamics
Proscaline acts as a serotonin 5-HT2 receptor agonist with activity at the 5-HT2A, 5-HT2B, and 5-HT2C receptors.4 It has been described as a partial agonist at the 5-HT2A receptor, activation of which is thought to be responsible for its psychedelic effects. Notably, proscaline displays considerably greater potency at the 5-HT2C receptor compared to the 5-HT2A or 5-HT2B receptors.4
Pharmacokinetics
Proscaline is considerably more lipophilic than mescaline or escaline (log P of 1.70 compared to 0.78 and 1.11, respectively), a property expected to favor blood-brain barrier permeability.2
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Full Tolerance
Tolerance to the effects of proscaline develops almost immediately following ingestion.
Baseline Reset
Approximately 7 days
Half Tolerance
Approximately 3 days
Cross Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely LowProscaline is described as non-habit-forming, and interest in using it may diminish with repeated use. Its use is most often characterized as self-regulating.
History & Culture
Proscaline was first synthesized and investigated by Czech chemist Otakar Leminger in 1972.5 The compound was subsequently synthesized by David E. Nichols, who published his work in the Journal of Medicinal Chemistry in 1977. Around this period, Alexander Shulgin…
Legality
International
Proscaline, 4-propoxy-3,5-dimethoxyphenethylamine, and 4-propoxy-3,5-DMPEA do not appear in the current INCB Yellow List for the 1961 Convention, the INCB Green List for the 1971 Convention, or Tables I and II of the 1988 Convention.
By Country
United StatesNot scheduledSchedule I
Not specifically scheduled under the Controlled Substances Act. However, sale for human consumption could potentially trigger prosecution under the Federal Analogue Act due to structural similarity to mescaline, a Schedule I substance.
NetherlandsIllegal (analog/blanket ban)Lijst IA
Opiumwet9
Since 1 July 2025, Proscaline is controlled in the Netherlands through the Opiumwet's Lijst IA group for substances derived from 2-phenethylamine. Its 3,5-dimethoxy and 4-propoxy phenyl substitutions and unsubstituted 2-aminoethyl side chain fall within that group’s permitted phenyl-ring alkoxy substituents and side-chain structure. Import, export, preparation, processing, sale, supply, transport, possession, and manufacture of a substance in Lijst IA are prohibited, subject to the Act’s specified medicinal, pharmaceutical, veterinary, precursor, and List I/II exceptions.
PolandIllegalI-P
Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139)1112
Proscaline (Proskalina; 2-(3,5-dimetoksy-4-propoksyfenylo)etyloamina) is listed as a Group I-P psychotropic substance in Poland's controlled-substances regulation, effective in that listing from 5 May 2023. Group I-P substances may be used only for research; unauthorized possession is punishable by up to three years' imprisonment, and unauthorized production, distribution, import, or supply is separately criminalized.
SwitzerlandIllegal (analog/blanket ban)Verzeichnis e
Proscaline (4-propoxy-3,5-DMPEA) is a controlled phenylalkylamine under number 315 of Verzeichnis e in Annex 6 to the Betäubungsmittelverzeichnisverordnung des EDI. The provision covers phenethylamine-derived substances with alkoxy substitution on the phenyl ring, which encompasses Proscaline's 3,5-dimethoxy-4-propoxy substitution pattern. Industrial and scientific use is excepted from control, but private use is not excepted.
GermanyIllegal (analog/blanket ban)NpSG
Neue-psychoaktive-Stoffe-Gesetz (NpSG)6
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016.6 Production, import with intent to distribute, administration to others, and trading are criminal offenses.7 Possession itself is prohibited but not subject to criminal penalty, though ordering may be prosecuted as incitement to market the substance.8
NorwayIllegal§ 5
Forskrift om narkotika (narkotikaforskriften)10
Proscaline is listed as 4-Propoksy-3,5-DMPEA (proskalin) in Norway's Narcotics Regulations and is prohibited under section 5. The prohibition covers manufacture, acquisition, sale and other transfer, import, export, storage, possession, and use; the Ministry may grant an exception for medical or scientific needs.
SwedenIllegalFörteckning I
Proscaline is listed in Sweden as Proskalin, with the chemical name 3,5-dimetoxi-4-propoxifenetylamin, in Förteckning I of the national narcotics schedules. The schedule defines List I as substances, plant material and fungi that normally have no medical use. Unauthorised possession, use, transfer, and manufacture for misuse are narcotics offences under the Narcotics Criminal Act.
References
Source Pages
Bluelight: Proscaline Discussion
Erowid Experience Vault: Fully Psychedelic in the Most Subtle of Ways- Erowid Experience Vault: Mind Candy (50mg)
- Erowid Experience Vault: Nothing Extreme (102mg)
- Erowid: Proscaline Experience Vault
Isomer Design (TiHKAL/PiHKAL)- Isomer Design PiHKAL #140: Proscaline
PsychonautWiki
TripSit Factsheets
Wikipedia
Citations
- Shulgin AT, & Shulgin A. (1991). PiHKAL #140 P: Proscaline. PiHKAL: A Chemical Love Story. https://erowid.org/library/books_online/pihkal/pihkal140.shtml123
- Adam L Halberstadt, Muhammad Chatha, Stephen J Chapman, & Simon D Brandt. (March 2019). Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. J Psychopharmacol, 33(3), 406–414. https://doi.org/10.1177/02698811198266101234
- Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel, Marius C. Hoener, & Matthias E. Liechti. (2021). Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines. Front Pharmacol, 12. https://doi.org/10.3389/fphar.2021.7942541
- ==Interactions== {{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes}} ==Pharmacology== ===Pharmacodynamics=== Proscaline is a [[serotonin]] [[5. (n.d.). https://doi.org/10.1038/s41467-023-44016-112
- Otakar Leminger. (1972). Příspěvek k chemii v jádře alkoxylovaných β-fenoetylaminů – II: O některých v jádře alkoxylovaných β-fenoetylaminech, resp. jejich sulfátech. Chemický Průmysl, 22, 553–557. https://isomerdesign.com/bitnest/external/ChemickyPrumysl/22.5531
- Neue-psychoaktive-Stoffe-Gesetz (NpSG) — Inkrafttreten und Anlage 1 (Von 2-Phenethylamin abgeleitete Verbindungen). Bundesamt für Justiz (2016). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html12
- § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html1
- § 3 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__3.html1
- Opiumwet. wetten.overheid.nl (n.d.). https://wetten.overheid.nl/BWBR0001941/2025-07-011
- Forskrift om narkotika (narkotikaforskriften). lovdata.no (n.d.). https://lovdata.no/dokument/SF/forskrift/2013-02-14-199/KAPITTEL_1-11
- Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2024/1139/text.html1
- Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2023/1939/text.html1
- Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. lakemedelsverket.se (n.d.). https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf1
- Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/narkotikastrafflag-196864_sfs-1968-64/1
- Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (BetmVV-EDI) — Anhang e, Nummer 130. Bundeskanzlei / EDI (2022). https://www.fedlex.admin.ch/eli/cc/2011/363/de1
- Betäubungsmittelverzeichnisverordnung des EDI (BetmVV-EDI), Anhang 6, Ziff. 315. res.cloudinary.com (n.d.). https://res.cloudinary.com/adminch/image/private/s--aGGgd8MH--/v1773719628/Bundespublikationen/812-121-11d.pdf1
- Misuse of Drugs Act 1971 — Schedule 2, Part I, paragraph 1(c). UK Parliament (1971). https://www.legislation.gov.uk/ukpga/1971/38/schedule/212
- 21 CFR § 1308.11(d). ecfr.gov (n.d.). https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.111
- 21 CFR § 1308.11(d). uscode.house.gov (n.d.). https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section813&num=0&edition=prelim1
Further Reading
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Proscaline article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.